A Clinical Trial to Assess the Safety and Immunogenicity of Nanocovax in Heathy Volunteers

Inclusion Criteria: * From 18 to 50 years old in phase 1, from 12 to 75 years old in phase 2 * Body Mass Index (BMI) between 18 and 28 kg/m2 * The subject has good health, is assessed through medical history, clinical examination, and laboratory tests (such as hematology, biochemistry, urine ...) within the normal range evaluated by the clinician. * Subjects aged potentially pregnant should use effective contraceptive methods 4 weeks prior to screening and during the study and last until 6 months after the last injection. * Able and willing to participate in all activities in the clinical trial, including 6-month follow-up after vaccination. * Sign the consent form. For a subject from 12 to 17 years old, it is necessary to have a legal guardian sign the consent form to participate in the study Exclusion Criteria: * Insufficient civil act capacity. * Subjects at high risk of SARS-CoV-2 infection. * Subject is/has ever had any acute or chronic medical condition, including but not limited to: * Have any inflammatory disease, respiratory tract infection, have any respiratory symptoms such as: cough, sore throat, difficulty breathing, wheezing due to respiratory symptoms within 07 days before screening. Fever (armpit temperature ≥ 37°C) for 3 days before vaccination. * History of any chronic respiratory illness such as bronchial asthma, chronic bronchitis, cystic fibrosis, chronic obstructive pulmonary disease (COPD). * Malignant disease * Immune disorders, using immun…